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Mycophenolic acid is a commonly used immunosuppressant
after organ transplantation and in autoimmune diseases;
however, myelosuppression is a major complication despite
its largely favorable side-effect profile. Mycophenolic acid
targets inosine monophosphate dehydrogenase, which is
essential for T-cell proliferation. The T-cell cytokine
interleukin-17 (IL-17 or IL-17A) and its receptor maintain
normal neutrophilic granulocyte numbers in mice by
induction of granulocyte-colony-stimulating factor. To test
whether mycophenolic acid induces neutropenia by
inhibiting IL-17-producing T cells, we treated C57Bl/6 mice
with mycophenolate-mofetil (the orally available pro-drug)
and found a dose-dependent decrease in blood neutrophils.
This myelosuppressive effect was completely abolished in
mice that lack the IL-17 receptor. Mycophenolic acid delayed
myeloid recovery after bone marrow transplantation and
decreased the percentage of IL-17-producing T cells in the
spleen and thymus, and inhibited IL-17 production in human
and mouse T cells in vitro. Injection of IL-17 during
mycophenolic acid treatment overcame the suppression of
the circulating neutrophil levels. Our study shows that
mycophenolic acid suppresses neutrophil production by
inhibiting IL-17 expression, suggesting that measurement of
this interleukin might be useful in estimating the risk of
neutropenia in clinical settings.
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Myelosuppression is a common and potentially life-threaten-
ing side effect of immunosuppressive therapy. While some
drugs such as cyclophosphamide or azathioprine directly and
dose dependently affect myeloid cell proliferation and
idiosyncratic neutropenia is a dose and time independent
phenomenon not limited to immunosuppressives,1 myco-
phenolic acid (MPA)-induced neutropenia is dose-depen-
dent, but occurs typically more than 3 months after initiation
of treatment. The incidence of leukopenia was 19% at a daily
dose of 2 g and 38% at 3 g during 1 year in a large clinical trial
of renal transplant patients.2 A retrospective analysis of 78
liver-transplanted patients treated with the orally available
prodrug mycophenolate mofetil showed a 17% incidence of
neutropenia during a mean follow-up of 56 months.3 During
maintenance immunosuppressive regimens after solid organ
transplantation, rates of neutropenia ranged from 6 to 28%
in 6- to 12-month observations.4–7 Plasma MPA is mostly
albumin-bound and glucuronated to biologically active and
inactive forms that can in turn alter MPA albumin binding
and thereby biological activity.8–10 Despite association of
lower drug levels with delayed graft function and rejection,
and higher levels with toxicity, clinical trials have not yet
shown a clinical benefit of therapeutic drug monitoring in
renal transplant recipients.11,12
In addition to being part of most standard regimens after
organ transplantation,13,14 MPA is also used for treatment of
autoimmune diseases including lupus nephritis15,16 and anti-
neutrophil- cytoplasmic antibody-associated vasculitis.17,18
Therefore, understanding the mechanism of and possibly
identifying the risk factors for developing neutropenia may
become relevant for an extended cohort of patients.
MPA inhibits inosine monophosphate dehydrogenase
(IMPDH), the rate-limiting enzyme in de novo guanosine
biosynthesis that catalyzes the step from inosine monopho-
sphate to xanthosine monophosphate.19 Two IMPDH iso-
forms are encoded by separate genes, IMPDHI and IMPDHII.
MPA has a fivefold higher affinity for IMPDHII, which is
upregulated in activated lymphocytes requiring de novo GMP
synthesis.20,21 MPA has been shown to preferentially inhibit
B- and T-lymphocyte proliferation.22 It does not affect the
survival of T-lymphocytes in the G1 phase of the cell cycle,
but reduces the proliferation of both CD4þ and CD8þ
T cells.23 Addition of GMP, the final product of IMPDH,
reverted these effects. MPA has differential effects on T-cell
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cytokine production. Pharmacological inhibition or genomic
deletion of IMPDH did not change interleukin (IL)-2 or IL-2
receptor expression.24 The TH1 signature cytokine interferon-g
(IFN-g) was unchanged after IMPDHI genomic disruption,
but decreased in ex vivo models of pharmacological
inhibition.25,26 Secretion of the TH2 marker cytokines IL-4
and IL-5 was reduced.24
MPA has been studied in different animal models of
inflammatory renal disease. MPA ameliorated experimental
lupus nephritis in MRL/lpr mice,27 mercury-induced glo-
merulonephritis28 and Heymann nephritis in rats29 where
reduced IL-4 mRNA in immunization site draining lymph-
nodes and reduced mRNA expression of both IFN-g and IL-4
in renal cortex mononuclear cells was found.
Granulocyte-colony-stimulating factor (G-CSF) is the
major specific granulopoietic agent.30–32 It is produced by a
variety of cell types including bone marrow stromal and
epithelial cells. However, T cells are critically involved in
maintaining normal neutrophil blood counts.33 Nude mice
that lack thymic epithelium and therefore mature T cells have
low neutrophil counts that were reconstituted by adoptive
transfer of CD4þ T cells.34 G-CSF is strongly induced by the
T-cell cytokine IL-17, also known as IL-17A.35,36 Neutrophil
counts were decreased by approximately 40% in mice lacking
the IL-17 receptor (R)-A (Il17ra/).37,38 Bone marrow
regeneration after sub-lethal irradiation was impaired in mice
lacking IL-17RA signaling.39 Conversely, IL-17 overexpres-
sion resulted in marked neutrophilia.35,36 The effect of IL-17
on granulopoiesis is not direct, but requires secondary
mediators, such as G-CSF produced by bone marrow stromal
cells,40 fibroblasts,41 and epithelial cells.42,43
IL-17 is the signature cytokine of a novel TH subset, TH17
cells that are vastly expanded in a number of autoimmune
diseases.44 IL-17 is also made by gdþ and CD4ablow
T cells in normal mice.38,45 IL-17 production is induced by
a combination of IL-6 and transforming growth factor-b
(TGF-b) and maintained by IL-23.46–49 IL-17-producing
T cells have been implicated in pathological inflamma-
tion.44,50,51 However, IL-17 is also required in host defense
and acts largely by inducing neutrophil recruitment.52–54
The effect of MPA on IL-17 producer polarization has not
been investigated. Given that MPA acts on proliferating T cells,
we reasoned that the MPA effect on granulopoiesis might be
mediated by inhibition of T-cell proliferation, causing IL-17
producer depletion over time resulting in reduced G-CSF and
decreased granulopoiesis. We therefore investigated the effect
of MPA on IL-17-producing T cells in vitro and in vivo.
RESULTS
MPA dose dependently decreases circulating neutrophil
counts in mice
To test whether MPA reduced blood neutrophil counts in
mice similar to that in humans and rats,55 we treated C57Bl/6
mice with the clinical dose of 30 mg/kg for 10 weeks. This
significantly reduced circulating blood neutrophil counts
(Figure 1a). To test whether reduced neutrophil counts
during MPA treatment were attributable to the IL-17
pathway, we used mice deficient in the main IL-17
receptor-A (Il17ra/). As reported previously,37,38 Il17ra/
mice have reduced neutrophil counts (Figure 1b). Their
level of neutrophils was unaffected by MPA treatment
(30 mg/kg) for 10 weeks (Figure 1b). In a separate experiment
using wild-type (wt) mice, a trend toward reduced neutrophil
counts was already evident at 4 weeks of MPA administration
at 30 mg/kg (Figure 1c). With this short-term treatment, a
higher dose of MPA (200 mg/kg) significantly reduced blood
neutrophil counts (Figure 1c). Both treatments were well
tolerated (Supplementary Figure 1a and b). Concerning other
hematopoietic cell lines, lymphocyte counts were decreased
as expected in the peripheral blood and there also was a slight
but significant decrease in erythrocyte counts (Supplemen-
tary Figure 1c and d). These data show that MPA treatment
reduces blood neutrophil counts in normal mice, and that
this effect requires IL-17 receptor-A.
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Figure 1 |MPA treatment depresses neutrophil counts in C57Bl/6 but not Il17ra/ mice. Eight-week-old wt C57Bl/6 were treated
with 30mg/kg/day mycophenolate (MPA) (triangles) or left untreated (circles) for 10 weeks. MPA treatment significantly decreased
neutrophil counts (a) (n¼ 4–5, *Po0.05). To test if the effect of MPA on neutrophil counts was related to IL-17, 7- to 9-week-old
IL-17-receptor-deficient (Il17ra/) mice were treated with 30mg/kg/day MPA (triangles) or left untreated (circles) for 10 weeks
(b, conducted in parallel with a) (n¼ 4–7). In a separate experiment, to test for dose response and short-term effects, 4-month-old
female C57Bl/6 mice were treated with either 30 or 200mg/kg/day MPA for 4 weeks (c). Neutrophil counts were significantly decreased after
high-dose treatment (n¼ 4–7, *Po0.05).
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MPA inhibits T-cell proliferation and polarization to IL-17
production in vitro
We next studied the dose response of MPA-mediated inhibition
of T-cell proliferation and cytokine production. Total spleno-
cytes were stained with curboxyfluorescein-succinimidyl-ester
(CFSE) and stimulated with anti-CD3 and anti-CD28 for
3 days. Treatment with MPA resulted in a dose-dependent
decrease in CD4þ T-cell proliferation (Figure 2a and b). To test
if the mouse oral treatment regimen resulted in sufficient
plasma levels to inhibit T-cell proliferation, 10% MPA-treated
(30 mg/kg per day) or control mouse plasma was added to the
culture media. Plasma from MPA-treated mice significantly
reduced T-cell proliferation as measured by CFSE dilution
(Figure 2c). The inhibition observed after addition of 10%
MPA-treated mouse plasma corresponded to 0.16±0.09mg/ml
exogenous MPA and thereby a plasma concentration of 1.6mg/
ml after 10 dilution. Previous reports have shown that MPA
can inhibit the production of a number of T-cell cytokines such
as the TH1 marker cytokine IFN-g
26 and the TH2 marker
cytokines IL-4 and IL-5.24 To test how these were inhibited
under non-lineage-specific T-cell stimulation (anti-CD3/anti-
CD28) as compared with IL-17, cells were restimulated with
phorbol-12-myristate-13-acetate (PMA)/ionomycin and super-
natants were assessed for IFN-g, IL-5, and IL-17 (Figure 2d–f).
IL-17 production was significantly inhibited at 0.2mg/ml MPA,
when there was only a trend toward decreased IFN-g, whereas
significant IFN-g and IL-5 inhibition required 2mg/ml MPA,
suggesting higher sensitivity of IL-17 producers to MPA.
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Figure 2 |MPA inhibits T-cell proliferation in vitro and ex vivo. Total splenocytes were stained with CFSE, treated with MPA or buffer
control, and proliferation among live, CD4þ cells was assessed after 3 days on anti-CD3 and anti-CD28 (a, a typical example and b, means of
three independent experiments). (c) 10% mouse plasma from MPA-treated or control mice was added to the culture and proliferation was
assessed as in panel a. The TH1 marker cytokine IFN-g (d), the TH2 marker cytokine IL-5 (e), and the TH17 marker cytokine IL-17 (f) were
assessed in the supernatants of splenocytes cultured on anti-CD3 and anti-CD28 for 3 days (dimethylsulfoxide control versus 2 and
0.2mg/ml MPA, n¼ 4) (*Po0.05). CFSE, curboxyfluorescein-succinimidyl-ester.
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To more specifically investigate the effect of MPA on
IL-17 production, we cultured wt mouse splenocytes under
TH17-polarizing conditions with IL-6, TGF-b, and IL-23.
38,46
IL-17A mRNA was assessed by real-time reverse transcription-
PCR after 20 h culture (Figure 3a). MPA dose dependently
reduced IL-17A mRNA. To test for specificity, GMP, the
product of IMPDH, the enzyme inhibited by MPA, was
added. IL-17 mRNA expression was restored by GMP. To test
if decreased mRNA resulted in decreased IL-17 protein
expression, a 6-day standard protocol (three days of IL-6,
TGF-b, and IL-23 treatment with stimulation on anti CD3/
anti-CD28 followed by 3 days of treatment with IL-6,
TGF-b, and IL-23 only) was used.38,46 On day 6, cells were
re-stimulated by PMA/ionomycin and IL-17 secretion into
the supernatant was measured by ELISA (Figure 3b). MPA
dose dependently reduced IL-17 secretion. To investigate IL-17
biosynthesis at the single-cell level, we measured intracellular
IL-17 after 6 days of IL-6, TGF-b, and IL-23 treatment
(Figure 3c). On average, the number of IL-17-producing cells
was reduced by 74% upon MPA treatment (Figure 3d).
To test whether MPA directly affected IL-17-producing
CD4þ T cells or acted indirectly through another cell
type, the experiment was repeated in sorted CD4þ cells.
Flow cytometry of polarized CD4þ cells stained for
intracellular IL-17 again showed a dose-dependent decrease
of IL-17-producing cells by MPA treatment (Figure 3e).
To test if these results were also applicable to human
lymphocytes, human peripheral blood mononuclear cells
were polarized toward IL-17 production by IL-6 and
TGF-b.56 Flow cytometry after intracellular staining showed
a significant decrease when MPA (2 mg/ml) was added to the
culture medium (Figure 4a and b). No such decrease was
observed when the culture media was supplemented with
GMP (Figure 4c). Tissue culture supernatants were examined
for secreted IL-17A by ELISA and again there was a
significant decrease in MPA-treated cells’ media (Figure 4d)
that was no longer present after addition of GMP (Figure 4e).
These data show a dose-dependent and IMPDH-specific
effect of MPA on IL-17 production from mouse and human
lymphocytes.
MPA inhibits neutrophil recovery and differentiation of
IL-17-producing splenocytes in vivo
To test the effects of MPA on IL-17 producer differentiation
in vivo, we reconstituted lethally irradiated mice with
autologous bone marrow and subjected them to 4 weeks of
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Figure 3 |MPA inhibits in vitro polarization of IL-17-producing T cells. Total splenocytes were polarized toward IL-17 production using
IL-6, TGF-b, and IL-23 on anti-CD3 and anti-CD28. After 20 h, IL-17A mRNA was assessed with and without addition of 100 mM GMP (a)
(quantitative real-time PCR compared with b-actin, values in % of dimethylsulfoxide control, n¼ 5–6). After 3 days of stimulation, cells were
transferred to an untreated plate, rested for 3 days, and re-stimulated with PMA/ionomycin for 5 h. IL-17A secretion into the supernatant
was measured by ELISA (b, n¼ 4). The percentage of IL-17 producers among live CD3þ cells was assessed by flow cytometry (c) and
quantified (d, n¼ 5) (*Po0.05, **Po0.01). To test whether this effect was directly exercised on T cells, CD4þ splenocytes were isolated
and treated with MPA (0.02, 0.2, and 2 mg/ml). IL-17 production was analyzed by flow cytometry after intracellular staining (e, a typical
of three independent experiments).
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MPA treatment or left them untreated. As expected, MPA
induced peripheral blood lymphopenia (Supplementary
Figure 2a) and also decreased the peripheral blood red cell
but not the thrombocyte counts (Supplementary Figure 3a
and b). MPA suppressed blood neutrophil counts at 2 weeks
of reconstitution (Figure 5a). There was no evidence of
morphological changes in blood neutrophils by MPA
treatment (Supplementary Figure 3a). Bone marrow cellu-
larity in MPA-treated mice was decreased (Supplementary
Figure 4b), but little change in bone marrow granulocyte Gr1
or 7/4 expression levels was observed (Supplementary Figure
4a and b).
IL-17 production in the splenocytes of the bone marrow-
transplanted mice was assessed by flow cytometry (Figure 5b;
total cell numbers are given in Supplementary Figure 2b). As
described previously,45 most IL-17A producers among CD3þ
splenocytes were not CD4þ , but rather CD4lowab-TCRlow
Their number among all splenocytes was reduced by 60%
at 2 weeks and by 31% at 4 weeks in splenocytes from
MPA-treated mice (Figure 5c). Similar results were found in
thymocytes (Supplementary Figure 2c and d). This resulted
in a significant decrease of the total number of IL-17-
producing cells per organ. These data suggest that MPA
inhibits the recovery of IL-17-producing T cells after bone
marrow transplantation.
Treatment with IL-17 normalizes circulating neutrophil
numbers in MPA-treated mice during hematopoietic recovery
To test whether depression in circulating neutrophil counts
by MPA was indeed due to lack of IL-17 rather than direct
effects, for example, on myeloid progenitors or G-CSF-
producing cells, we assessed whether IL-17 can reconstitute
circulating neutrophil counts in MPA-treated mice. MPA-
treated bone marrow-transplanted mice were intraperitone-
ally injected with 1 mg IL-17 or phosphate-buffered saline
control on day 10 after bone marrow transplantation. This
resulted in increased blood neutrophil counts at day 14
(Figure 6a). IL-17-induced rescue of blood neutrophil counts
was associated with elevated plasma G-CSF levels in the same
mice (Figure 6b). No significant change in circulating
lymphocyte and erythrocyte levels was observed after
injection of IL-17 (Supplementary Figure 5c and d). To test
if IL-17 could also normalize circulating neutrophil levels in
otherwise unchallenged mice treated with MPA, mice were
treated for 4 weeks and then received an intraperitoneal IL-17
injection. This significantly increased circulating neutrophil
counts after 3 days (Figure 6c). These results support the
notion that MPA-mediated neutropenia is due to a defect in
IL-17-producing T cells while downstream mediators can
respond sufficiently to IL-17.
The bone marrow produces G-CSF in response to IL-17
stimulation with the highest expression of IL-17 receptor
on CD115þCD11bþ monocytes
IL-17 induces G-CSF production from a number of tissues
and cell types, including bone marrow stromal cells,40
fibroblasts,41 and epithelial cells.42,43 Under homeostatic
conditions in vivo, it has not been determined which organ
or cell type is the main G-CSF producer. To start investigating
this question, we first stimulated cell suspensions from a
number of different organs (spleen, mesenteric lymph nodes,
thymus, small intestine, bone marrow) and assessed the
supernatants by ELISA for G-CSF production. Of all organs
studied, G-CSF concentration was highest in bone marrow
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Figure 4 |Mycophenolate inhibits polarization of human IL-17-producing T cells. Human peripheral blood mononuclear cells
were polarized toward IL-17 production using IL-6 and TGF-b. IL-17 production in live CD4þ cells was assessed by flow cytometry
after intracellular staining (a). (b) Shown is the mean reduction in IL-17-producing cells by addition of 2 mg/ml MPA from n¼ 5 donors
(***Po0.001). When GMP was added to the culture medium no reduction in the percentage of IL-17 producers was observed (c, n¼ 5).
IL-17 production was also studied by ELISA of tissue culture supernatants. There was a significant reduction by MPA at concentrations
of 0.2 and 2 mg/ml (d, n¼ 3, *Po0.05). No such decrease was observed in the presence of GMP (e, n¼ 3).
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supernatants (Figure 7a). To test if these G-CSF producers
were sensitive to IL-17 stimulation, bone marrow was
treated with IL-17 (50 mg/ml for 5 h). This increased
G-CSF secretion (Figure 7b). To investigate which cell
type expressed the IL-17 receptor, bone marrow was analyzed
by multicolor flow cytometry. The highest IL-17 receptor
expression was found on CD115þCD11bþ monocytes
(Figure 7c). These results suggest bone marrow and
monocytic cells as a relevant source of IL-17-dependent
G-CSF production.
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Figure 6 |Mycophenolate-induced decrease in neutrophil counts is rescued by IL-17. To test if IL-17A limited neutrophil recovery,
mice were injected intraperitoneally with 1 mg recombinant IL-17A on day 10. Neutrophil counts (a, n¼ 6–7 from three independent
experiments) and plasma G-CSF levels (b, n¼ 3–4, line: untreated controls) on day 14 were significantly increased by IL-17 treatment
(*Po0.05, **Po0.01). To test if IL-17 replacement was also effective in mice treated with MPA without previous hematopoietic challenge,
8-week-old male C57Bl/6 mice were treated with MPA (200mg/kg) for 4 weeks as in Figure 1c and received 1 mg recombinant IL-17A.
Neutrophil counts were determined at the start, 4 weeks, and on day 3 after IL-17A injection (c, n¼ 5, ***Po0.001; Bonferroni after one-way
analysis of variance).
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DISCUSSION
Our data show that MPA decreases circulating neutrophil
counts in mice, MPA treatment suppresses T cell IL-17
production, IL-17 induces G-CSF production from bone
marrow, and IL-17 substitution reverses MPA-induced
decrease in peripheral blood neutrophil counts.
Neutropenia in MPA-treated patients is a typical dose-
dependent and dose-limiting side effect. The late onset of
neutropenia in patients, commonly after several months of
treatment,2,57 suggested a mechanism distinct from direct
myelotoxic effects of other agents such as cyclophosphamide
or purine antagonists. We observed a decrease in circulating
neutrophil counts in normal wt, but not Il17ra/ mice. This
suggests that decrease in neutrophil counts by MPA is indeed
an IL-17-mediated effect.
MPA acts on replicating, but not resting T cells.23 Our
data confirm a dose-dependent inhibition of T-cell prolifera-
tion. Renewal of all T cells is necessary after an acute event
such as lethal irradiation and bone marrow transplantation,
and a significant decrease of IL-17-producing T cells was
observed in spleens of MPA-treated mice recovering from this
event. However, T-cell renewal also occurs under steady-state
conditions.58 In addition and differential from classical TH1
and TH2 cells, IL-17 production is not only a terminal T-cell
differentiation step but also a transient phenotype during
T-cell development in vivo.59–61 The generation of these
transient IL-17 producers might also be susceptible to
MPA. All mentioned mechanisms can reduce the amount of
IL-17A available for induction of G-CSF production and
thereby granulopoiesis.
Neutrophil counts in IL-17-receptor-deficient mice sug-
gest that IL-17 is responsible for 40–50% of normal
neutrophil counts in mice,38 and other IL-17-independent
mechanisms of G-CSF induction exist. One candidate among
the T-cell-produced mediators is oncostatin-M, which has
been reported to regulate hematopoietic progenitor cell
homeostasis.62 As MPA-induced depression of circulating
neutrophil counts was absent in Il17ra/ mice, this suggests
that the oncostatin-M pathway may be of minor importance
under the conditions studied here.
T-cell cytokine secretion is differentially affected by
pharmacological inhibition of IMPDH. While IL-2 produc-
tion remained unaffected, IFN-g, IL-4, and IL-5 were
significantly reduced by pharmacological inhibition in
vitro.24,26 We explored the effects of MPA on IL-17
production, the signature cytokine of the recently defined
TH17 lineage. Our data show strong inhibition of in vitro TH17
polarization induced by a combination of IL-6, IL-23, and
TGF-b, and activating the T cells by anti-CD3 and anti-CD28
in mouse and human lymphocytes. This is similar to recent
reports of IL-17 production in unpolarized human lympho-
cytes after 2–3 days,63,64 but not after 12-h short-term
stimulation.65 As IMPDHII activity is required for response
to anti-CD3 and anti-CD28 stimulation,66,67 a decrease of
IL-17 producer polarization using this mechanism is not
unexpected. However, also under non-TH17-specific condi-
tions in vitro and during acute recovery from irradiation and
bone marrow transfer in vivo, IL-17 production was reduced
in relation to other T cells or their respective cytokines. These
data raises the notion that IL-17 production may be more
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Figure 7 | The bone marrow secretes G-CSF in response to IL-17, and IL-17 receptor is highly expressed on bone marrow
CD115þCD11bþ monocytes. Stimulation with PMA/ionomycin for 5 h and ELISA were used to determine the presence of potential G-CSF
producers in a variety of tissues (a, n¼ 3–7). Production from bone marrow (BM) was higher than from spleen, mesenteric lymph nodes
(MLN), thymus, and small intestine (SI). BM G-CSF production was increased by IL-17 (b, 50 mg/ml for 5 h, n¼ 5). IL-17 receptor-A expression
on BM cells was studied by flow cytometry. The highest expression was found on CD115þCD11bþ monocytes (c, a typical example from
five wt animals, IL-17-receptor-deficient mice (Il17ra/ served as control, gates were set to include neutrophils (PMN), monocytes (Mo),
and lymphocytes (Ly)).
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sensitive to IMPDH inhibition than other T-cell cytokines,
which will require closer investigation.
In addition to maintenance of neutrophil counts,37,38 IL-17
acts as an acute inflammatory cytokine. Its role has been
shown in a broad range of autoimmune disease models,
including different forms of arthritis, colitis, and experi-
mental encephalitis.44,50,51 MPA is successfully used in a
number of conditions that are associated with high IL-17
levels such as renal allograft rejection68–70 and cardiac
allograft rejection characterized by massive neutrophil
infiltration in T-bet-deficient mice.71 Very recently, IL-17
has also been implicated in immune-mediated renal disease.
TH17 cells induced glomerulonephritis in response to antigens
planted on the glomerular basement membrane72 and
nephrotoxic nephritis.73 IL-23 induces and stabilizes the
population of IL-17-producing T cells.46,47 It was required for
development of nephrotoxic glomerulonephritis and glomer-
ulonephritis in response to immunization with the Good-
pasture antigen.73,74 A role for IL-17 has also been shown in a
mouse model of systemic lupus erythematosus, another
condition successfully treated with MPA.15,16,75 Here, we
exclusively study the role of MPA in regard to neutrophil
homeostasis, but our results suggest the hypothesis that the
benefit of MPA in autoimmune diseases and graft rejection is
at least partially due to inhibition of TH17 cells.
Reversal of MPA-induced decrease in peripheral blood
neutrophil numbers by IL-17 raises the question whether
IL-17 is a possible intervention in MPA-induced neutro-
penia. From the role of IL-17 in autoimmune diseases,
this appears counter-intuitive and would require extensive
safety research. However, IL-17 application in an otherwise
non-inflammatory setting was well tolerated during adeno-
viral overexpression35 and injection of recombinant protein
in our study. It is also of note that the pathogenicity of
IL-17 very much depends on the cytokine context, especially
IL-2351 and on the producing cell type, that is, CD4þ versus
gdþ– or CD4 ablow T cells. As a much less experimental
approach, G-CSF application as the mainstay of treatment
in neutropenia has been sucessfully used in MPA-induced
neutropenia in patients according to anecdotal reports.76
In cases of neutropenia that are not anticipated, but already
severe at detection, the value of G-CSF therapy has been
questioned,77 because endogenous G-CSF levels are elevated.
If depression of granulopoiesis by MPA is due to lack of IL-17
and thereby G-CSF induction rather than direct myelotoxi-
city as our data suggest, G-CSF application is mechanistically
more plausible and avoids the need to substitute IL-17.
Our data suggest that IL-17 levels might be investigated as
an indicator of neutropenia risk during MPA treatment.
While circulating IL-17 levels are below the detection limit of
commonly used assays in normal mice,38 they are detectable
in normal human serum, albeit at low concentrations.70,78
Our findings provide a mechanistic explanation of a
common and treatment-limiting MPA side effect. This could
open new avenues for risk assessment and possibly manage-
ment of MPA-induced neutropenia.
MATERIALS AND METHODS
Animals
Wt C57Bl/6 mice (Jackson Labs, Bar Harbor, ME, USA) and mice
lacking IL-17 receptor (Il17ra/) (95% C57Bl/6 background)40 were
genotyped by PCR and used in age- and sex-matched groups. They
were kept in specific pathogen-free conditions in a barrier facility.
Animal experiments were approved by the Animal Care Committee
at LIAI. Lethal irradiations were performed in a 137Cesium irradiator
(600 rad twice, 3 h apart) and mice were reconstituted with
unfractioned wt bone marrow. Mycophenolate mofetil (Roche
Pharma AG, Grenzach-Wyhlen, Germany) was incorporated into
the chow (Research diets, New Brunswick, NJ, USA) at 300 mg/kg
and 2 g/kg. This was calculated to reach an oral dose of 30 or 200 mg/
kg body weight/day, respectively, at a chow consumption of 0.1 g/g.
The measured chow consumption was 0.14±0.02 g/g body weight
per day in the low-dose and 0.15±0.01 g/g body weight per day in
the high-dose treatment and 0.15±0.03 g/g body weight per day in
the control groups (no significant differences). Recombinant IL-17A
was from Peprotech (Rocky Hill, NJ, USA). Differential blood leukocyte
counts were recorded using EDTA-coated capillary tubes, analyzed using
an automatic analyzer (Hemavet 950; CDC Technologies, Oxford, CT,
USA), and differential counts were confirmed manually (Sure stain,
Fisher, Middletown, VA, USA).
Lymphocyte polarization, stimulation, staining, and flow
cytometry
To induce IL-17 production, mouse total splenocytes or CD4þ cells
sorted using the EasySep Mouse CD4þ T-cell-negative selection kit
(Stemcell Technologies, Vancouver, BC, Canada), according to the
manufacturer’s instructions, were stimulated in complete medium
(RPMI-1640 containing 10% fetal bovine serum, non-essential
amino acids, 2 mM L-glutamine (all from Invitrogen, Carlsbad, CA,
USA), and 1% penicillin/streptomycin) by plate-bound purified
anti-CD28 and anti-CD3 (Biolegend, San Diego, CA, USA) in the
presence of IL-6 (50 ng/ml), TGF-b (1 ng/ml; Peprotech), and IL-23
(20 ng/ml; eBioscience, San Diego, CA, USA) with the indicated
concentrations of MPA with and without GMP (100 mM) (both
Sigma-Aldrich, Saint Louis, MO, USA) or dimethylsulfoxide-solvent
control for 3 days. Human peripheral blood mononuclear cells were
obtained by density-gradient centrifugation and cultured on anti-
human CD28 and anti-CD3 (Biolegend, San Diego, CA, USA) using
human IL-6 (50 ng/ml) and TGF-b (1 ng/ml; Peprotech). Before re-
stimulation for flow cytometry or ELISA analysis, cells were
transferred to an untreated plate and rested for 3 days. Polarized
splenocytes and cell suspensions from spleen and thymus were
stimulated for 5 h with 10 ng/ml PMA, 500 ng/ml calcium ionophore
(both Sigma-Aldrich, Saint Louis, MO, USA), and 2 mM monensin
(eBioscience, San Diego, CA, USA). Anti-mouse-CD3a-PerCP-
Cy5.5 (145-2C11), anti-mouse-CD4-PerCP (RM4-5), anti-mouse-
TCRb-APC (H57-597), anti-mouse IL-17A-PE (TC11-18H10.1),
anti-mouse IL-17RA-PE (5G4), anti-mouse CD115-APC (AFS98),
anti-mouse CD11b-Pacific blue (M1/70), anti-human IL-17A-PE
(eBio64CAP17), and anti-human CD4-FITC (OKT4) (eBioscience
and Biolegend, San Diego, CA, USA) were used with the LIVE/
DEAD Fixable Dead Cell Stain kit (Invitrogen, Carlsbad, CA, USA)
and BD-Fix-Perm (BD PharMingen, San Jose, CA, USA). CFSE
labeling was performed using the Celltrace CFSE cell proliferation
kit (Invitrogen). Flow cytometry was performed using a Becton-
Dickinson FACS Calibur or LSRII. Data were analyzed using the
FlowJo software (Tree Star, Ashland, OR, USA). Gates for IL-17A
were set using Il17a/ cells79 (excluding 99.9% of cells).
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mRNA quantification
RNA was isolated using Trizol (Invitrogen) and reverse transcribed
using the Omniscript RT kit (Qiagen, Valencia, CA, USA) after
DNAse digest (RNAse free DNAse; Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Real-time PCR was
performed using the QuantiTect SYBR Green reverse transcription-
PCR kit (Qiagen) using a Lightcycler 480 (Roche, Indianapolis, IN,
USA). The primers for Il17a were selected using primer bank80
as follows: TTTAACTCCCTTGGCGCAAAA (forward), CTTTCCC
TCCGCATTGACAC (reverse). Transcript levels were normalized to
b-actin according to the DCT method.
ELISA
Mouse IL-17A and G-CSF were assayed using Duo-Set ELISA
development kits (R&D Systems, Minneapolis, MN, USA), IFN-g
and IL-5 using the mouse Th1/Th2 cytokine kit (BD PharMingen),
and human IL-17A using ELISA Ready-SET-Go (eBioscience)
according to the manufacturer’s instructions.
Statistical analysis
Two-tailed Student’s t-test or paired t-test was used after analysis of
variance if more than two values were compared. Data are expressed
as mean±s.e.m.
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